PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
;
Isabel
Dos-Santos-Silva
;
Olivia
Fletcher
;
Nichola
Johnson
;
Manjeet K
Bolla
;
Elinor J
Sawyer
;
Ian
Tomlinson
;
Michael J
Kerin
;
Nicola
Miller
;
Federik
Marme
;
Barbara
Burwinkel
;
Rongxi
Yang
;
Pascal
Guénel
;
Thérèse
Truong
;
Florence
Menegaux
;
Marie
Sanchez
;
Stig
Bojesen
;
Sune F
Nielsen
;
Henrik
Flyger
;
Javier
Benitez
;
M Pilar
Zamora
;
Jose Ignacio Arias
Perez
;
Primitiva
Menéndez
;
Hoda
Anton-Culver
;
Susan
Neuhausen
;
Argyrios
Ziogas
;
Christina A
Clarke
;
Hermann
Brenner
;
Volker
Arndt
;
Christa
Stegmaier
;
Hiltrud
Brauch
;
Thomas
Brüning
;
Yon-Dschun
Ko
;
Taru A
Muranen
;
Kristiina
Aittomäki
;
Carl
Blomqvist
;
Natalia V
Bogdanova
;
Natalia N
Antonenkova
;
Annika
Lindblom
;
Sara
Margolin
;
Arto
Mannermaa
;
Vesa
Kataja
;
Veli-Matti
Kosma
;
Jaana M
Hartikainen
;
Amanda B
Spurdle
;
kConFab
Investigators
;
Australian Ovarian Cancer Study Group
;
Els
Wauters
;
Dominiek
Smeets
;
Benoit
Beuselinck
;
Giuseppe
Floris
;
Jenny
Chang-Claude
;
Anja
Rudolph
;
Petra
Seibold
;
Dieter
Flesch-Janys
;
Janet E
Olson
;
Celine
Vachon
;
Vernon S
Pankratz
;
Catriona
McLean
;
Christopher A
Haiman
;
Brian E
Henderson
;
Fredrick
Schumacher
;
Loic
Le Marchand
;
Vessela
Kristensen
;
Grethe Grenaker
Alnæs
;
Wei
Zheng
;
David J
Hunter
;
Sara
Lindstrom
;
Susan E
Hankinson
;
Peter
Kraft
;
Irene
Andrulis
;
Julia A
Knight
;
Gord
Glendon
;
Anna Marie
Mulligan
;
Arja
Jukkola-Vuorinen
;
Mervi
Grip
;
Saila
Kauppila
;
Peter
Devilee
;
Robert AEM
Tollenaar
;
Caroline
Seynaeve
;
Antoinette
Hollestelle
;
Montserrat
Garcia-Closas
;
Jonine
Figueroa
;
Stephen J
Chanock
;
Jolanta
Lissowska
;
Kamila
Czene
;
Hatef
Darabi
;
Mikael
Eriksson
;
Diana M
Eccles
;
Sajjad
Rafiq
;
William J
Tapper
;
Sue M
Gerty
;
Maartje J
Hooning
;
John WM
Martens
;
J Margriet
Collée
;
Madeleine
Tilanus-Linthorst
;
Per
Hall
;
Jingmei
Li
;
Judith S
Brand
;
Keith
Humphreys
;
Angela
Cox
;
Malcolm WR
Reed
;
Craig
Luccarini
;
Caroline
Baynes
;
Alison M
Dunning
;
Ute
Hamann
;
Diana
Torres
;
Hans Ulrich
Ulmer
;
Thomas
Rüdiger
;
Anna
Jakubowska
;
Jan
Lubinski
;
Katarzyna
Jaworska
;
Katarzyna
Durda
;
Susan
Slager
;
Amanda E
Toland
;
Christine B
Ambrosone
;
Drakoulis
Yannoukakos
;
Anthony
Swerdlow
;
Alan
Ashworth
;
Nick
Orr
;
Michael
Jones
;
Anna
González-Neira
;
Guillermo
Pita
;
M Rosario
Alonso
;
Nuria
Álvarez
;
Daniel
Herrero
;
Daniel C
Tessier
;
Daniel
Vincent
;
Francois
Bacot
;
Jacques
Simard
;
Martine
Dumont
;
Penny
Soucy
;
Rosalind
Eeles
;
Kenneth
Muir
;
Fredrik
Wiklund
;
Henrik
Gronberg
;
Johanna
Schleutker
;
Børge G
Nordestgaard
;
Maren
Weischer
;
Ruth C
Travis
;
David
Neal
;
Jenny L
Donovan
;
Freddie C
Hamdy
;
Kay-Tee
Khaw
;
Janet L
Stanford
;
William J
Blot
;
Stephen
Thibodeau
;
Daniel J
Schaid
;
Joseph L
Kelley
;
Christiane
Maier
;
Adam S
Kibel
;
Cezary
Cybulski
;
Lisa
Cannon-Albright
;
Katja
Butterbach
;
Jong
Park
;
Radka
Kaneva
;
Jyotsna
Batra
;
Manuel R
Teixeira
;
Zsofia
Kote-Jarai
;
Ali Amin Al
Olama
;
Sara
Benlloch
;
Stefan P
Renner
;
Arndt
Hartmann
;
Alexander
Hein
;
Matthias
Ruebner
;
Diether
Lambrechts
;
Els
Van Nieuwenhuysen
;
Ignace
Vergote
;
Sandrina
Lambretchs
;
Jennifer A
Doherty
;
Mary Anne
Rossing
;
Stefan
Nickels
;
Ursula
Eilber
;
Shan
Wang-Gohrke
;
Kunle
Odunsi
;
Lara E
Sucheston-Campbell
;
Grace
Friel
;
Galina
Lurie
;
Jeffrey L
Killeen
;
Lynne R
Wilkens
;
Marc T
Goodman
;
Ingo
Runnebaum
;
Peter A
Hillemanns
;
Liisa M
Pelttari
;
Ralf
Butzow
;
Francesmary
Modugno
;
Robert P
Edwards
;
Roberta B
Ness
;
Kirsten B
Moysich
;
Andreas
du Bois
;
Florian
Heitz
;
Philipp
Harter
;
Stefan
Kommoss
;
Beth Y
Karlan
;
Christine
Walsh
;
Jenny
Lester
;
Allan
Jensen
;
Susanne Krüger
Kjaer
;
Estrid
Høgdall
;
Bernard
Peissel
;
Bernardo
Bonanni
;
Loris
Bernard
;
Ellen L
Goode
;
Brooke L
Fridley
;
Robert A
Vierkant
;
Julie M
Cunningham
;
Melissa C
Larson
;
Zachary C
Fogarty
;
Kimberly R
Kalli
;
Dong
Liang
;
Karen H
Lu
;
Michelle AT
Hildebrandt
;
Xifeng
Wu
;
Douglas A
Levine
;
Fanny
Dao
;
Maria
Bisogna
;
Andrew
Berchuck
;
Edwin S
Iversen
;
Jeffrey R
Marks
;
Lucy
Akushevich
;
Daniel W
Cramer
;
Joellen
Schildkraut
;
Kathryn L
Terry
;
Elizabeth M
Poole
;
Meir
Stampfer
;
Shelley S
Tworoger
;
Elisa V
Bandera
;
Irene
Orlow
;
Sara H
Olson
;
Line
Bjorge
;
Helga B
Salvesen
;
Anne M
van Altena
;
Katja KH
Aben
;
Lambertus A
Kiemeney
;
Leon FAG
Massuger
;
Tanja
Pejovic
;
Yukie
Bean
;
Angela
Brooks-Wilson
;
Linda E
Kelemen
;
Linda S
Cook
;
Nhu D
Le
;
Bohdan
Górski
;
Jacek
Gronwald
;
Janusz
Menkiszak
;
Claus K
Høgdall
;
Lene
Lundvall
;
Lotte
Nedergaard
;
Svend Aage
Engelholm
;
Ed
Dicks
;
Jonathan
Tyrer
;
Ian
Campbell
;
Iain
McNeish
;
James
Paul
;
Nadeem
Siddiqui
;
Rosalind
Glasspool
;
Alice S
Whittemore
;
Joseph H
Rothstein
;
Valerie
McGuire
;
Weiva
Sieh
;
Hui
Cai
;
Xiao-Ou
Shu
;
Rachel T
Teten
;
Rebecca
Sutphen
;
John R
McLaughlin
;
Steven A
Narod
;
Catherine M
Phelan
;
Alvaro N
Monteiro
;
David
Fenstermacher
;
Hui-Yi
Lin
;
Jennifer B
Permuth
;
Thomas A
Sellers
;
Y Ann
Chen
;
Ya-Yu
Tsai
;
Zhihua
Chen
;
Aleksandra
Gentry-Maharaj
;
Simon A
Gayther
;
Susan J
Ramus
;
Usha
Menon
;
Anna H
Wu
;
Celeste L
Pearce
;
David
Van Den Berg
;
Malcolm C
Pike
;
Agnieszka
Dansonka-Mieszkowska
;
Joanna
Plisiecka-Halasa
;
Joanna
Moes-Sosnowska
;
Jolanta
Kupryjanczyk
;
Paul Dp
Pharoah
;
Honglin
Song
;
Ingrid
Winship
;
Georgia
Chenevix-Trench
;
Graham G
Giles
;
Sean V
Tavtigian
;
Doug F
Easton
;
Roger L
Milne
;
(2016)
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
Journal of medical genetics, 53 (12).
pp. 800-811.
ISSN 0022-2593
DOI: 10.1136/jmedgenet-2016-103839
BACKGROUND: The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate precisely associated cancer risks. Population-based family studies have provided evidence that at least some of these mutations are associated with breast cancer risk as high as those associated with rare BRCA2 mutations. We aimed to estimate the relative risks associated with specific rare variants in PALB2, CHEK2 and ATM via a multicentre case-control study. METHODS: We genotyped 10 rare mutations using the custom iCOGS array: PALB2 c.1592delT, c.2816T>G and c.3113G>A, CHEK2 c.349A>G, c.538C>T, c.715G>A, c.1036C>T, c.1312G>T, and c.1343T>G and ATM c.7271T>G. We assessed associations with breast cancer risk (42 671 cases and 42 164 controls), as well as prostate (22 301 cases and 22 320 controls) and ovarian (14 542 cases and 23 491 controls) cancer risk, for each variant. RESULTS: For European women, strong evidence of association with breast cancer risk was observed for PALB2 c.1592delT OR 3.44 (95% CI 1.39 to 8.52, p=7.1×10-5), PALB2 c.3113G>A OR 4.21 (95% CI 1.84 to 9.60, p=6.9×10-8) and ATM c.7271T>G OR 11.0 (95% CI 1.42 to 85.7, p=0.0012). We also found evidence of association with breast cancer risk for three variants in CHEK2, c.349A>G OR 2.26 (95% CI 1.29 to 3.95), c.1036C>T OR 5.06 (95% CI 1.09 to 23.5) and c.538C>T OR 1.33 (95% CI 1.05 to 1.67) (p≤0.017). Evidence for prostate cancer risk was observed for CHEK2 c.1343T>G OR 3.03 (95% CI 1.53 to 6.03, p=0.0006) for African men and CHEK2 c.1312G>T OR 2.21 (95% CI 1.06 to 4.63, p=0.030) for European men. No evidence of association with ovarian cancer was found for any of these variants. CONCLUSIONS: This report adds to accumulating evidence that at least some variants in these genes are associated with an increased risk of breast cancer that is clinically important.
-
picture_as_pdf - jmedgenet-2016-103839.pdf
-
subject - Published Version
-
- Available under Creative Commons: Attribution-NonCommercial-No Derivative Works 3.0